ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

More Bad News for AVEO As Tivozanib Partner Bids Adieu

May 31, 2013

ACS Reorganization Plans, Policy Changes Discussed By Board

November 29, 1991

NCAB Defends Organ Site Program, But DeVita Still Plan to Discuss It With Cancer Panel

October 17, 1980

ACS Probably Will Accept Hammer’s Offer On Matching Funds For Survey

February 3, 1984

DCE Board Okays New Melanoma Study, Other Concepts

November 11, 1988

AACR Selects Eight Finalists To Compete For $15 Million Grants Funded By Telethon.

December 5, 2008